Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000250 | 1.00 | TET2 (0.50) | TET2ACLYALDH1A1TSHRPOLB | |
| SCHEMBL28220010 | 0.91 | TET2 (0.44) | TET2ACLYALDH1A1TSHRPOLB | |
| SCHEMBL1196173 | 0.83 | ALDH1A1 (0.44) | TET2ACLYALDH1A1TSHRTHRB | |
| SCHEMBL22440902 | 0.83 | ALDH1A1 (0.44) | TET2ACLYALDH1A1TSHRTHRB | |
| SCHEMBL1197211 | 0.83 | ALDH1A1 (0.44) | TET2ACLYALDH1A1TSHRTHRB | |
| SCHEMBL387177 | 0.83 | ALDH1A1 (0.44) | TET2ACLYALDH1A1TSHRTHRB | |
| SCHEMBL26348118 | 0.80 | TET2 (0.47) | TET2ACLYALDH1A1TSHRPOLB | |
| SCHEMBL6437940 | 0.77 | POLB (0.35) | TET2ALDH1A1POLBNPSR1 | |
| SCHEMBL10932999 | 0.77 | TET2 (0.44) | TET2ACLYMEN1CYP1A2KMT2A | |
| SCHEMBL11418482 | 0.76 | TSHR (0.45) | TET2ACLYALDH1A1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1155138-B1 | METHOD FOR PREPARING OPTICALLY ACTIVE 3,3,3-TRIFLUOROMETHYL-2-ALKYL PROPIONIC ACID DERIVATIVES | LONZA AG (CH) | 2005-01-05 | — | — | EP | claimed |
| US-12492182-B2 | Hydroxytriazine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2025-12-09 | — | — | US | disclosed |
| US-20240076278-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-03-07 | — | — | US | disclosed |
| US-20230305398-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| EP-4046991-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2022-08-24 | — | — | EP | disclosed |
| CN-108137515-B | Hydroxy triazine compound and medical use thereof | 日本烟草产业株式会社 | 2021-07-06 | — | — | CN | disclosed |
| US-20210024486-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-01-28 | — | — | US | disclosed |
| EP-3339296-A1 | HYDROXYTRIAZINE COMPOUND AND MEDICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-20170057943-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-03-02 | — | — | US | disclosed |
| US-8614081-B2 | Nitrilase biocatalysts | CODEXIS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999044618-A1 | CHEMICAL COMPOUNDS AND THEIR USE TO ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 1999-09-10 | — | — | WO | disclosed |
| US-5700798-A | Methods for using benzoxazines for treating asthma | ZENECA LIMITED (GB) | 1997-12-23 | — | — | US | disclosed |
| EP-0698022-B1 | 1,4-BENZOXAZINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | ZENECA LTD (GB) | 1997-09-17 | — | — | EP | disclosed |
| EP-0698022-A1 | 1,4-BENZOXAZINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | ZENECA LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| US-5486515-A | 2-fluoroalkyl-1,4-benzoxaxines as potassium channel mediators | ZENECA LIMITED (GB) | 1996-01-23 | — | — | US | disclosed |
| WO-1994026739-A1 | 1,4-BENZOXAZINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | ZENECA LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| EP-0002892-B1 | AMIDE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL OR VETERINARY COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-02-06 | — | — | EP | disclosed |
| US-4191775-A | ANTIANDROGENIC | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-03-04 | — | — | US | disclosed |
| EP-0002892-A1 | Amide derivatives, process for their manufacture and pharmaceutical or veterinary compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024486-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGS1, PTGIS, PTGES | TET2 3926/4885ACLY 2301/4885ALDH1A1 618/4885 |
| US-20240076278-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGS1, PTGIS, PTGES | TET2 3926/4885ACLY 2301/4885ALDH1A1 618/4885 |
| US-12492182-B2 | Hydroxytriazine compounds and pharmaceutical use thereof | PTGS1, PTGIS, PTGES | TET2 3926/4885ACLY 2301/4885ALDH1A1 618/4885 |
| US-20170057943-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGS1, PTGIS, PTGES | TET2 3926/4885ACLY 2301/4885ALDH1A1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.